Immupharma (LSE: IMM) share were off moderately to 6.85pp with a £20m Mkt Cap after reporting another step in the agonizing journey to achieve FDA approval for its International Stage 3 clinical trial for its Lupuzor drug target. A new phrase in the drug approval process maybe required, its a pharmacokinetic (PK) trial. PK is the study of the time and course of drug absorption, distribution, metabolism and excretion.
The Lupuzor drug is for the treatment of the chronic inflammatory disease Lupus, where there been no new treatments for many years and it is ...
